RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer

Treatment evaluation in metastatic castration-resistant prostate cancer is challenging. There is an urgent need for biomarkers to discriminate short-term survivors from long-term survivors, shortly after treatment initiation. Thereto, the added value of early RNA biomarkers on predicting progression...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers 2021-12, Vol.13 (24), p.6279
Hauptverfasser: Boerrigter, Emmy, Benoist, Guillemette E, van Oort, Inge M, Verhaegh, Gerald W, de Haan, Anton F J, van Hooij, Onno, Groen, Levi, Smit, Frank, Oving, Irma M, de Mol, Pieter, Smilde, Tineke J, Somford, Diederik M, Hamberg, Paul, Dezentjé, Vincent O, Mehra, Niven, van Erp, Nielka P, Schalken, Jack A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Treatment evaluation in metastatic castration-resistant prostate cancer is challenging. There is an urgent need for biomarkers to discriminate short-term survivors from long-term survivors, shortly after treatment initiation. Thereto, the added value of early RNA biomarkers on predicting progression-free survival (PFS) and overall survival (OS) were explored. The RNA biomarkers: mRNA, miR-375, miR-3687, and were measured in 93 patients with mCRPC, before and 1 month after start of first-line abiraterone acetate or enzalutamide treatment, in two prospective clinical trials. The added value of the biomarkers to standard clinical parameters in predicting PFS and OS was tested by Harell's C-index. To test whether the biomarkers were independent markers of PFS and OS, multivariate Cox regression was used. The best prediction model for PFS and OS was formed by adding miR-375 and (at baseline and 1 month) to standard clinical parameters. Baseline miR-375 and detectable after 1 month of therapy were independently related to shorter PFS, which was not observed for OS. In conclusion, the addition of and miR-375 (at baseline and 1 month) to standard clinical parameters resulted in the best prediction model for survival assessment.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers13246279